Bill Detail
H.R. 4780
Congress: 119
Title
USTRx Act
Summary
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States. The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.
Sponsor
Rep. Jodey Arrington [R-TX-19]
Status
Referred to the House Committee on Ways and Means.
Status as of Oct 2, 7:27 AM · synced 9h ago
Introduced
2025-07-29
Data source mode: cache
Bill Engagement
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR).
Lobbyists on the case
- Pharmaceutical Research and Manufacturers of America2 filings · 17 lobs
- Catherine Douglas2026 Q1
- Bart Forsyth2026 Q1
Prepared intelligence brief
Connect the event to the surrounding activity.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.